| IEX |
Report |
Adj. EPS (Q2 2026) |
BEAT |
pred ~$2.17 vs. cons ~$2.10 |
HIGH |
| IEX |
Report |
Organic Revenue Growth (Q2 2026) |
BEAT |
pred ~+4.7% vs. cons +3.69% |
MEDIUM |
| IEX |
Report |
HST Segment Revenue (Q2 2026) |
BEAT |
pred ~$420M vs. cons $406M |
MEDIUM |
| IEX |
Guide |
Adj. EPS (Q3 2026) |
UNCHANGED |
guide ~$2.20 vs. cons $2.19 |
MEDIUM |
| IEX |
Guide |
Adj. EPS (FY 2026) |
BETTER |
guide ~$8.65 midpoint vs. cons ~$8.45 |
MEDIUM |
| IEX |
Guide |
Organic Growth (FY 2026) |
BETTER |
guide ~4.5% midpoint vs. cons +3.99% |
MEDIUM |
| IEX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+5.0% |
— |
MEDIUM |
| IEX |
Return |
5-day cumulative residual |
+5.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — FY guide raise pulls H2 estimates up; sell-side revisions drive follow-through over 3-5 days |
MEDIUM |